L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 10:07:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 338 TO ITERATE

100.0% PROCESSED 338 ITERATIONS 144 ANSWERS
SEARCH TIME: 00.00.01

L2 144 SEA SSS FUL L1

=> d 1-10

L2 ANSWER 1 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 959750-29-9 REGISTRY
ED Entered STN: 30 Dec 2007
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(3-methyl-2-furanyl)methyl]phenylamino]carbonyl]oxy]-, (3-endo)- (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H29 N2 O3
CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 2 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 959745-39-2 REGISTRY
ED Entered STN: 30 Dec 2007
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(3-methyl-2-furanyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H29 N2 O3 . Br
SR CA
LC STN Files: CA, CAPLUS, CASREACT
CRN (959750-29-9)

Relative stereochemistry.



● Br^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-70-2 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(4-penten-1-yl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(4-pentenyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (9CI)
FS STEREOSEARCH
MF C23 H31 N2 O2 S2
CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 4 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-69-9 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(3-phenoxypropyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 N2 O3 S2
CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 5 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-68-8 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-[4-(phenylmethoxy)butyl]-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H37 N2 O3 S2

CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 6 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-67-7 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(3-phenylpropyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 N2 O2 S2
CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 7 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-66-6 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(2-phenylethyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H31 N2 O2 S2
CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 8 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-65-5 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(phenylmethyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H29 N2 O2 S2
CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 9 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-64-4 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-[2-(2-methoxyethoxy)ethyl]-8-methyl-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H33 N2 O4 S2
CI COM
SR CA

Relative stereochemistry.



L2 ANSWER 10 OF 144 REGISTRY COPYRIGHT 2008 ACS on STN
RN 868208-63-3 REGISTRY
ED Entered STN: 16 Nov 2005
CN 8-Azoniabicyclo[3.2.1]octane, 8-(5-hexen-1-yl)-8-methyl-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 8-Azoniabicyclo[3.2.1]octane, 8-(5-hexenyl)-8-methyl-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3-endo,8-anti)- (9CI)
FS STEREOSEARCH
MF C24 H33 N2 O2 S2
CI COM
SR CA

Relative stereochemistry.



=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	198.82	199.03

FILE 'CAPLUS' ENTERED AT 10:08:03 ON 10 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Nov 2008 VOL 149 ISS 20
FILE LAST UPDATED: 9 Nov 2008 (20081109/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 2 L2

=> d 1-2 bib abs hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1170495 CAPLUS
DN 148:55231
TI Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists
AU Laine, Dramane I.; Xie, Haibo; Buffet, Noemie; Foley, James J.; Buckley, Peter; Webb, Edward F.; Widdowson, Katherine L.; Palovich, Michael R.; Belmonte, Kristen E.
CS GlaxoSmithkline, King of Prussia, PA, 19406, USA
SO Bioorganic & Medicinal Chemistry Letters (2007), 17(22), 6066-6069
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:55231
GI



I



II

AB In the course of a research program to develop novel muscarinic receptor antagonists for the treatment of COPD, new tropine carbamate derivs., such as I and II [R1 = Ph, R2 = Ph, 2-, 3- thienyl, 5-methyl-2-thienyl,

3-methyl-2-thienyl, 3-furanyl, 3-methyl-2-furanyl, C6H4-2-Br, -3-Br, -4-Br, -3-OMe, -4-OMe, -4-CN; R1 = 2-thienyl, R2 = Ph; R1 = 3-thienyl, R2 = Ph, 3-thienyl, cyclohexyl, C6H4-4-CN], were identified as potent anti-muscarinic agents. The synthesis, structure-activity relationships and pharmacol. evaluation that led to the identification of 8-azoniabicyclo[3.2.1]octane carbamate II (R1 = 3-thienyl, R2 = Ph).

IT 868078-99-3P 868079-00-9P 868079-02-1P
868079-04-3P 868079-05-4P 868079-11-2P
868079-18-9P 868079-23-6P 868079-35-0P
868079-42-9P 868080-19-7P 868080-24-4P
868080-25-5P 868080-26-6P 868080-27-7P
868080-28-8P 868080-29-9P 959745-39-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists)

RN 868078-99-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-00-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[(phenylmethyl)-3-thienylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-02-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-04-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-05-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[(phenylmethyl)-2-thienylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-11-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-18-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(5-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-23-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[(cyclohexylmethyl)-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-35-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[(3-furanylmethyl)phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-42-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(3-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-19-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-cyanophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-24-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-cyanophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-25-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-methoxyphenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-26-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-bromophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-27-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-bromophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-28-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-bromophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-29-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-methoxyphenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 959745-39-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(3-methyl-2-furanyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1154378 CAPLUS
DN 143:422258
TI Preparation of 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists.
IN Laine, Dramane I.; Palovich, Michael R.; Xie, Haibo; Buffet, Noemie
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005099706	A2	20051027	WO 2005-US11975	20050407
	WO 2005099706	A3	20060511		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732923	A2	20061220	EP 2005-737620	20050407
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
	JP 2007538005	T	20071227	JP 2007-507532	20050407
	US 20070238751	A1	20071011	US 2006-599717	20061006
PRAI	US 2004-560155P	P	20040407		
	WO 2005-US11975	W	20050407		

OS CASREACT 143:422258; MARPAT 143:422258
GI



I

AB Title compds. [I; R1 = bond, H, alkyl; R2 = H, alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, etc.; R3, R4 = (substituted) Ph, thienyl, furyl, cycloalkyl; n = 0-2; X = pharmaceutically acceptable counterion], were prepared for treatment of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, (3-endo)-8-azabicyclo[3.2.1]oct-3-ylmethyl [(2-fluorophenyl)methyl]-2-thienylcarbamate trifluoroacetate (preparation given) was stirred with MeBr and NaHCO3 in CH2Cl2/Me3COMe for 16 h to give (3-endo)-3-[[[[[(2-fluorophenyl)methyl](2-thienyl)amino]carbonyl]oxy]methyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide.

IT 868078-99-3P 868079-00-9P 868079-01-0P
868079-02-1P 868079-03-2P 868079-04-3P

868079-05-4P 868079-06-5P 868079-07-6P
868079-08-7P 868079-09-8P 868079-10-1P
868079-11-2P 868079-12-3P 868079-13-4P
868079-18-9P 868079-23-6P 868079-26-9P
868079-28-1P 868079-35-0P 868079-42-9P
868079-50-9P 868079-51-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azoniabicyclooctane carbamates as muscarinic
acetylcholine receptor antagonists)

RN 868078-99-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-00-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[(phenylmethyl)-3-thienylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-01-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-fluorophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-02-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-03-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-fluorophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-04-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-05-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[(phenylmethyl)-2-thienylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-06-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-fluorophenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-07-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-fluorophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-08-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-fluorophenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-09-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-fluorophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-10-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-fluorophenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-11-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-12-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2,4-difluorophenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-13-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868079-18-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(5-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-23-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[(cyclohexylmethyl)-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-26-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-(6-hydroxyhexyl)-8-methyl-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-28-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-fluorophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-35-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[(3-furanylmethyl)phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-42-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(3-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-50-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-bromophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-51-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(5-methyl-2-furanyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

IT 868079-57-6P 868079-96-3P 868079-97-4P
868079-98-5P 868079-99-6P 868080-00-6P
868080-19-7P 868080-20-0P 868080-21-1P
868080-22-2P 868080-24-4P 868080-25-5P
868080-26-6P 868080-27-7P 868080-28-8P
868080-29-9P 868080-30-2P 868080-31-3P
868080-32-4P 868080-33-5P 868080-39-1P
868080-57-3P 868080-58-4P 868080-59-5P
868080-60-8P 868080-61-9P 868080-62-0P
868080-63-1P 868080-64-2P 868080-65-3P
868080-71-1P 868080-94-8P 868080-95-9P
868080-96-0P 868080-97-1P 868080-98-2P
868080-99-3P 868081-00-9P 868081-01-0P
868081-02-1P 868081-04-3P 868081-06-5P
868081-08-7P 868081-10-1P 868081-12-3P
868081-14-5P 868081-16-7P 868081-17-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azoniabicyclooctane carbamates as muscarinic acetylcholine receptor antagonists)

RN 868079-57-6 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 8,8-dimethyl-3-[[[[(phenylmethyl)-2-thienylamino]carbonyl]oxy]methyl]-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868079-96-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[[(2-fluorophenyl)methyl]-2-thienylamino]carbonyl]oxy]methyl]-8,8-dimethyl-, bromide (1:1), (3-endo)-(CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-97-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[[(3,5-difluorophenyl)methyl]-3-thienylamino]carbonyl]oxy]methyl]-8,8-dimethyl-, bromide (1:1), (3-endo)-(CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-98-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[[(3-fluorophenyl)methyl]-3-thienylamino]carbonyl]oxy]methyl]-8,8-dimethyl-, bromide (1:1), (3-endo)-(CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868079-99-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[[(4-cyanophenyl)methyl]-2-thienylamino]carbonyl]oxy]methyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-00-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[[[4-(1,1-dimethylethyl)phenyl]methyl]-2-thienylamino]carbonyl]oxy]methyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-19-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-cyanophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-20-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-methoxyphenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-21-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-bromophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-22-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-bromophenyl)methyl]-3-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-24-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-cyanophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-25-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-methoxyphenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-26-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-bromophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-27-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-bromophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-28-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-bromophenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-29-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-methoxyphenyl)methyl]phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-30-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-bromophenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-31-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-bromophenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-32-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-bromophenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-33-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(4-methoxyphenyl)methyl]-2-thienylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-39-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(2-fluoro-5-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]methyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868080-57-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[cyclopentyl[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-58-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-bromophenyl)methyl]cyclopentylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-59-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[cyclopentyl[(3-fluorophenyl)methyl]amino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-60-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[cyclopentyl(phenylmethyl)amino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-61-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[cyclohexyl[(2-fluorophenyl)methyl]amino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-62-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[cyclopentyl[(2-fluorophenyl)methyl]amino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-63-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[cyclohexyl[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-64-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[[(3-bromophenyl)methyl]cyclohexylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-65-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[cycloheptyl[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-71-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-94-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(3-phenoxypropyl)-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-95-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-propyl-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-96-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-(5-hexen-1-yl)-8-methyl-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-97-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-[2-(2-methoxyethoxy)ethyl]-8-methyl-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-98-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(2-phenylethyl)-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868080-99-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(3-phenylpropyl)-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868081-00-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-[4-(phenylmethoxy)butyl]-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868081-01-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(phenylmethyl)-3-[[[3-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 868081-02-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-propyl-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868081-04-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-(5-hexen-1-yl)-8-methyl-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868081-06-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-[2-(2-methoxyethoxy)ethyl]-8-methyl-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868081-08-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(phenylmethyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868081-10-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(2-phenylethyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



RN 868081-12-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(3-phenylpropyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



RN 868081-14-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-[4-(phenylmethoxy)butyl]-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868081-16-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(3-phenoxypropyl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 868081-17-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-8-(4-penten-1-yl)-3-[[[2-thienyl(3-thienylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3-endo,8-anti)- (CA INDEX NAME)

Relative stereochemistry.



=>